Steven Pergam

Adjunct Associate Professor, Epidemiology
Associate Professor, Medicine - Allergy and Infectious Dis.



MD University of Nebraska, 1998
MPH Epidemiology, University of Washington, 2008



Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave. N, E4-100
Seattle, WA 98109
View Website »


Dr. Pergam is an Infectious Diseases physician and researcher who received his MD from the University of Nebraska School of Medicine, his Infectious Diseases fellowship training at the University of Washington (UW), and his MPH from the UW School of Public Health. Dr. Pergam serves as the Medical Director of Infection Prevention at the Seattle Cancer Care Alliance (SCCA). Dr. Pergam focuses his research on the prevention and treatment of infections among immunocompromised patients, and has expertise in infection prevention and hospital epidemiology among cancer and transplant patients. He serves on numerous national committees, including the CDC’s Advisory Committee on Immunization Practices, and the National Comprehensive Cancer Network Committee on the Prevention and Treatment of Infections in Cancer. He also is an Associate Editor for BMC Infectious Diseases and Current Opinions in Infectious Diseases.

Research Interests

Dr. Pergam’s research interests involve hospital epidemiology, antimicrobial resistance, and infection prevention in immunosuppressed hosts. His research group focuses on infection prevention, resistant pathogens, antimicrobial stewardship, and on the development of novel prevention strategies for community and healthcare-associated infections in cancer and hematopoietic cell transplant patients. He has active research projects that evaluate vaccinations, water-borne pathogens, resistant bacteria, respiratory virus transmission, and fungal infections among immunocompromised hosts. He is interested in the interplay between the immune response, the microbiome, bacterial and viral infections in the respiratory and gastrointestinal systems, and their association with inflammatory complications (e.g. Graft-versus-host disease, mucositis).

Recent Publications (PubMed)

Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center.
(2022 May 24)
Transplant Cell Ther
Lindsay J, Krantz EM, Morris J, Sweet A, Tverdek F, Joshi A, Yeh R, Hill JA, Greenwood M, Chen SC, Kong DCM, Slavin M, Pergam SA, Liu C

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
(2021 Nov)
Open Forum Infect Dis 8(11): ofab502
Lindsay J, Othman J, Kong Y, Yip A, Van Hal S, Larsen S, Bryant C, Gibson J, Kerridge I, Fay K, Stevenson W, Arthur C, Chen SCA, Kong DCM, Greenwood M, Pergam SA, Liu C, Slavin MA

Respiratory viruses in hematopoietic cell transplant candidates: impact of preexisting lower tract disease on outcomes.
(2022 Apr 21)
Blood Adv
Kim Y, Waghmare A, Xie H, Holmberg LA, Pergam SA, Jerome KR, Leisenring WM, Ogimi C, Campbell AP, Englund JA, Boeckh M

Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation.
(2022 Apr 15)
Leuk Lymphoma
Lindsay J, Greenwood M, Othman J, Chen SC, Kong DCM, Pergam SA, Liu C, Slavin MA

Cannabis use among patients with cutaneous lymphoma: A cross-sectional survey.
(2022 Aug)
Complement Ther Med 67(): 102830
Mahurin HM, Ware OR, Coolman TD, Stevenson PA, Pergam SA, Shinohara MM

Show complete publication list